Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis to be tested is that the bioavailability of the new 30-mg vial is similar to that of the current approved 15 -mg vials. In addition, the SC injection using the new 30-mg vial is safe and well-tolerated.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Healthy males or females between the ages of 21 and 55 years

Exclusion Criteria:

• Positive urine drug screen

• Excessive use of alcohol or nicotine-containing products

• Pregnant or nursing females